Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Preferred Stock Liabilities: 2019

Historic Preferred Stock Liabilities for Avidity Biosciences (RNA) over the last 1 years, with Dec 2019 value amounting to $134.7 million.

  • Avidity Biosciences' Preferred Stock Liabilities was N/A to $134.7 million in Q4 2019 from the same period last year, while for Dec 2019 it was $134.7 million, marking a year-over-year change of. This contributed to the annual value of $134.7 million for FY2019, which is N/A change from last year.
  • Latest data reveals that Avidity Biosciences reported Preferred Stock Liabilities of $134.7 million as of FY2019.
  • Over the past 5 years, Avidity Biosciences' Preferred Stock Liabilities peaked at $134.7 million during FY2019, and registered a low of $134.7 million during FY2019.
  • In the last 1 years, Avidity Biosciences' Preferred Stock Liabilities had a median value of $134.7 million in 2019 and averaged $134.7 million.